secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2026-09-28T20:01:53+00:00
Accession:  0001437749-26-031337
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Phio holders approve 1.5M-share increase to 2020 incentive plan; all six directors elected
--------------------------------------------------------------------------------

- Stockholders approved Amendment No. 1 raising shares issuable under the 2020 Long Term Incentive Plan by 1,500,000, to a total of 2,452,017 shares.
- Plan amendment passed with 1,155,945 votes for, 194,070 against, 34,468 abstained and 3,823,097 broker non-votes.
- All six directors elected to serve until the 2027 annual meeting; Robert J. Bitterman received 1,341,217 for and 43,266 withheld.
- Grant Thornton LLP ratified as independent auditor for fiscal 2026 by 5,087,608 for to 88,779 against; 31,193 abstained.
- 11,617,250 shares were outstanding as of the August 4, 2026 record date; 5,207,580 shares were represented at the September 28, 2026 meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000143774926031337/0001437749-26-031337-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000143774926031337/phio20260916_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-031337

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer